Kornimate/medical-research-clean huggingface dataset:
survey on sensory processing sensitivity in chronic pediatric pain

Conditions: Chronic Pain

Summary: background: pain is defined as an unpleasant sensory and emotional experience and in its chronic form, pain is highly prevalent, up to 25% of children and adolescents are affected by it. the exact etiology of many forms of chronic pain remains unknown. one mechanism that has been proposed to underlie increased pain sensitivity is central sensitization, i.e., increased efficacy of the nervous system in transmitting pain signals, which manifests itself as a lower pain threshold. a lower pain threshold in turn has been recognized as a risk factor for the development of chronic pain. being more sensitive to pain is one feature commonly shared by those with high sensory processing sensitivity (sps), who are thought to react more strongly to both positive and negative environmental influences. the relationship between this increased sensitivity and pain tolerance has not been studied to date, but could contribute to our understanding of why some children and adolescents are more vulnerable to developing chronic pain than others. objectives and aims: the aim of this project is to increase scientific understanding of 1) the distribution and correlates of high sps among children and adolescents suffering from chronic pain, and 2) whether the trait of sps can help explain increased pain sensitivity and hence vulnerability for chronic pain. methods: to determine the distribution (aim 1a) and correlates (aim 1b) of sps among a population of children and adolescents suffering from chronic pain, an online survey will be conducted. participants will be asked to complete questionnaires about their sps as well as pain history and pain characteristics. the distribution of sps will then be compared to an existing distribution in a sample of healthy children and adolescents.


Eligibility criteria:
inclusion criteria: * adolescents aged 17-19 years * persistent or recurrent pain for 3 months or more * fluent in german or english exclusion criteria: * younger than 17 or older than 19 years * acute pain
prolotherapy intervention in patient with frozen shoulder

Conditions: Frozen Shoulder

Summary: introduction : prolotherapy is regenerative tissue therapy that is considered to be efficacious in reducing symptoms and morbidity of frozen shoulder, but only a few studies demonstrate the effect of prolotherapy at the biomolecular level, particularly the level of matrix metalloproteinase- i (mmp-1), tissue inhibitor matrix metalloproteinase (timp-1), as the biomarkers of cartilage repair. objective: to determine the effect of prolotherapy on mmp-1, timp-1, and functional outcomes in frozen shoulder patients method: a double-blind randomized controlled trial study involving participants who had been diagnosed with frozen shoulder. history taking, functional outcome assessment, mmp-1, and timp-1 were measured. the prolotherapy via intraarticular and extraarticular was performed four times, followed by the evaluation of functional outcome, mmp-1, and timp-1 at week 12 alternative hypothesis : prolotherapy will increase the mmp-1, timp-1 levels, and improve functional outcome among frozen shoulder patients

design : double-blind randomized trial randomization : simple randomization generated by an online randomizer sample size : difference between two means of primary outcome where 1. mean difference (μ 1 - μ 2 ) = 0.47 2. pool variance = 0.09 3. z 1-α/2 = 1.95 with type 1 error 5% 4. 1-β = 1.282 with power 90%. yielding 16 patients for each arm detailed intervention 1. intervention group: prolotherapy is given four times (week 0, week 2, week 4, and week 6) 2. comparison group: normal saline is given four times with a timeframe similar to the intervention group injection location 1. rotator cuff muscles 2. intraarticular glenohumeral joint 3. subacromial bursa 4. long-heap of the biceps tendon 5. acromioclavicular joint statistical analysis : 1. descriptive statistic to elaborate baseline characteristic 2. assuming the baseline characteristic between groups are similar, the independent t-test will be conducted to see the differences between group, whereas mann whitney will be performed for nonparametric data 3. difference within-group (baseline and last day) will be measured by paired-t-test or wilcoxon for non parametric scenario

Eligibility criteria:
1. inclusion criteria 1. age 35-70 2. diagnosed with frozen shoulder 3. at least showing symptoms more than 3 months 2. exclusion criteria 1. receiving other intraarticular injection 2. taking nonsteroid antiinflammation drugs 1 week prior to intervention 3. skin disorder around the injection site 4. septic arthritis

Keywords: mmp-1 timp-1 prolotherapy functional outcome frozen shoulder
[al18f]psma137 pet/ct imaging for psma-positive cancer patients

Conditions: Prostate Cancer

Summary: to investigate the radioactive uptake of \[al 18 f\]psma137 in pca patients, and evaluate the ability of \[al 18 f\]psma137 to detect psma overexpression in pca patients (especially those with recurrent or advanced pca).to provide an approach for screening patients high expression of psma, efficacy monitoring, drug resistance and early warning of recurrence and metastasis to achieve the individualized antitumor treatment of targeted drugs.

prostate cancer (pca) is the most common malignant tumor in the male reproductive system, and its prognosis and treatment mainly depend on the discovery of the primary disease and the early stage of metastasis, while traditional imaging and histological methods are difficult to meet the clinical requirements for the early diagnosis and accurate staging of pca.positron emission tomography (pet) has the characteristics of precision and non-invasive, so the development of pca targeted molecular probe is of great significance for improving the specificity and accuracy of pca diagnosis. psma is a highly specific prostatic epithelial membrane antigen, which is highly expressed in solid tumors such as prostate cancer. more than 90% of prostate cancer cells express psma, so psma can be used as an important imaging target for prostate cancer. the radionuclides used for pet imaging include 18f (t 1/2 =109.8min), which has a suitable half-life and cyclotron preparation to enable the high yield synthesis of 18f labeled tracer, so it can be used in more patients and provided to other departments without on-site tracer production facilities.in addition, coordination labeling method is simple, easy to realize automatic synthesis technology and medicine box preparation.therefore, 18f-labeled psma targeted molecular probe is a hot spot in the diagnosis of prostate cancer. \[al18f\]psma137 is a novel psma targeted tracer labeled with 18f. nota is used as a bifunctional chelating agent to facilitate better chelation with al18f. it has a higher tumor uptake and a faster metabolism in normal organs with a lower background.\[al18f\]psma137, as a novel targeted molecular probe, shows excellent properties in tumor cell uptake.this project provides research on \[al18f\]psma137 pet/ct imaging for patients with suspected pca, and provides basis for early diagnosis of pca, formulation of treatment plan and efficacy evaluation.

Eligibility criteria:
inclusion criteria: * men over 18 years of age need to undergo \[al18f\]psma137 pet/ct examination for suspected prostate cancer. * the patients can fully understand and voluntarily participate in this experiment, and sign the informed consent. exclusion criteria: * significant hepatic or renal dysfunction; * patients with malignant tumors other than prostate cancer within 2 years; * ready to pregnant; * the patient can not tolerate all clinical tests.

Keywords: psma
study to assess the efficacy and safety of treatment of articular cartilage lesions with cartilife®

Conditions: Articular Cartilage Lesion of the Knee

Summary: the purpose of this study is to assess the safety and efficacy of implanting bead-type autologous chondrocyte (cartilife®) obtained by culturing expanded costal chondrocytes of the patient with a chondral defect in the knee. the patients will be assessed clinically using mri, clinical, biochemical and international knee documentation committee(ikdc) outcomes preoperatively as well as 8, 24 and 48 weeks postoperatively to assess the relief of symptoms and joint function.


Eligibility criteria:
inclusion criteria: * adult men and women aged between 19 and 65 * defect size: 2 to 10 ㎠ on the unilateral knee cartilage (up to 4 ㎤ in volume) * defect: isolated international cartilage repair society(icrs) grade iii or iv single defect chondral lesion on articular cartilage * the joint space is maintained over 50% relative to baseline * patients that are able to walk without aid * patients that agree to abide by strict rehabilitation protocols and follow-up programs * patients who provide written consent to the participation of the clinical trial exclusion criteria: * patients with inflammatory articular diseases such as rheumatoid arthritis or gouty arthritis * kellgren and lawrence grade ≥ 3 * patients with arthritis associated with autoimmune diseases * patients hypersensitive to bovine protein * patients with haemophilia or markedly reduced immune function * patients hypersensitive to antibiotics like gentamicin * patients with arterial bleeding and severe venous bleeding * patients with other diseases including tumors except for cartilaginous defects of joints * patients with a history of radiation treatment and chemotherapy within the past two years * patients who are pregnant, nursing a baby or likely to get pregnant * patients who participate in concurrent clinical trials or previous clinical trials within 30 days of administration * other cases where the investigator deems the patient ineligible for participation

Keywords: degenerative arthritis autologous chondrocyte implantation cartilage defects cartilage lesion arthritis
peptic ulcer perforation study

Conditions: Peptic Ulcer Perforation

Summary: the objective of this study is to implement an optimized perioperative course for patients surgically treated for peptic ulcer perforation in order to improve the outcome for these patients. the optimized perioperative course consists of a number of interventions carried out before, during and after surgery.


Eligibility criteria:
inclusion criteria: * patients surgically treated for benign peptic ulcer perforation exclusion criteria: * age \< 18 years * pregnant and breastfeeding women * malign ulcer perforation

Keywords: perforated peptic ulcer mortality
treatment of non-high-risk acute promyelocytic leukemia (apl) with realgar-indigo naturalis formula (rif)

Conditions: Acute Promyelocytic Leukemia

Summary: the investigators design a multicenter randomized controlled trial to prove that rif plus atra is possibly superior to ato plus atra as consolidation and maintenance treatment for the patients with non-high-risk apl.

acute promyelocytic leukemia (apl) is a unique subtype of acute myeloid leukemia (aml) which accounts for 10-15% of acute myeloid leukemia. it is characterized by the pml-rara fusion gene generated by the t(15;17)(q22;q21) chromosomal translocation. the application of atra and ato, make apl from highly fatal to highly curable. apl0406 study proves that atra plus arsenic trioxide is at least not inferior and may be superior to atra plus chemotherapy in the treatment of patients with non-high-risk apl. now, the arsenic trioxide has already became the based regimen as targeted first-line treatment without chemotherapy. a study shows that oral rif plus atra is not inferior to intravenous ato plus atra as maintenance treatment of apl. the investigators design a multicenter randomized controlled trial to prove that rif plus atra is possibly superior to ato plus atra as consolidation and maintenance treatment for the patients with non-high-risk apl. application of oral rif decrease the total hospitalization days.

Eligibility criteria:
inclusion criteria: * age 14 to 70 years * newly diagnosed apl with t(15;17)(q22;q12) * before treatment the peripheral blood white blood cell count≤10×109/l * patients who can complete the entire treatment process * patients or their families signed written informed consent exclusion criteria: * be allergic to the drug ingredient, the supplementary material or the allergic constitution person * cardiac insufficiency, renal insufficiency, significant arrhythmias, ekg abnormalities or other important organ dysfunction * combined with other malignant tumors * pregnant and lactating women * participants in other drug trials in the last 3 months * suffering from mental illness or other circumstances which unable to carry out the plan * other patients who were not suitable for the study

Keywords: acute promyelocytic leukemia realgar-indigo naturalis formula all-trans retinoic acid
receiving modified chemotherapy followed with radical resection after neoadjuvant chemotherapy

Conditions: Locally Advanced Gastric Cancer

Summary: for patients undergoing postoperative therapy for locally advanced gastric cancer after neoadjuvant chemotherapy, we assessed the utility of graded histologic regression of \<50% as the criterion of treatment change. sixty patients will be enrolled to randomize into two groups：receiving modified chemotherapy and receiving the original chemotherapy.

for patients undergoing postoperative therapy for locally advanced gastric cancer after neoadjuvant chemotherapy, we assessed the utility of graded histologic regression of \<50% as the criterion of treatment change. sixty patients will be enrolled to randomize into two groups：receiving modified chemotherapy and receiving the original chemotherapy. overall survival and disease-free survival will be observed between two groups.

Eligibility criteria:
inclusion criteria: * tnm stage of t2-t4 or positive regional lymph nodes, according to the american joint committee on cancer (ajcc) 7.0 staging system, verified by enhanced abdominal computed tomography (ct) and/or endoscopic ultrasound (eus), positron emission tomography (pet)/ct scan), with no evidence of distant metastases; * ecog performance status score ≤2 without serious heart, lung, liver, kidney, or hematological dysfunctions; * age ≥18 years old; * no previous chemotherapy, radiotherapy, or surgical treatment for gastric cancer; * gastrectomy was performed after preoperative chemotherapy if imaging studies did not confirm disease progression (according to the response evaluation criteria in solid tumors (recist)) ; * signed the informed consent form. exclusion criteria: * all do not reach the inclusion criteria
flexible catheter for insulin in diabetes

Conditions: Diabetic Ketoacidosis

Summary: use of a flexible subcutaneous catheter improves comfort in patients with dka compared to the usual treatment with a metal needle.

assess whether the use of a flexible subcutaneous catheter improves comfort in patients with dka compared to the usual treatment with a metal needle. compare the metabolic evolution of patients with dka using a flexible subcutaneous catheter for insulin administration vs. a metal needle.

Eligibility criteria:
inclusion criteria: * patients aged 5 to 18 years, admitted with diagnoses of dka. dka is defined when patients meets all the following biochemical baseline criteria (before initial hydration): * glucose\> 200 mg / dl * ph \< 7.3 * bicarbonate \< 15mmol/l. exclusion criteria: * patients referred from another institution with a different treatment, and those who requires intensive care on admission.
nerve-sparing, robot-assisted radical prostatectomy using a personalized, 3d-printed prostate model for selective resection of positive surgical margins

Conditions: Prostate Cancer

Summary: to optimize precision for secondary resection (sr) in frozen section (fs) controlled nerve-sparing robot-assisted radical prostatectomy (ns-rarp) by using a personalized 3d-printed prostate model.

background: nerve-sparing (ns) robot-assisted radical prostatectomy (rarp) offers optimized oncological and functional outcomes and has become the preferred minimally-invasive approach when available. to maximize oncologic safety in ns-rarp, a frozen section (fs) can be used but does not provide a visual impression of the positive surgical margin (psm) to guide secondary resection (sr). objective: to optimize precision for secondary resection (sr) in frozen section (fs) controlled nerve-sparing robot-assisted radical prostatectomy (ns-rarp) by using a personalized 3d-printed prostate model. design, setting and participants: 100 patients with ns-rarp performed between september 2018 and august 2021 were included in this prospective multicenter cohort study. interventions: a prostate model was 3d printed from preoperative pelvic mri data and used during surgery to mark a psm and guide sr. outcome measurements and statistical analysis endpoints were comparison of the primary surgical margin status in the fs with the tissue of the resulting sr and with the final surgical margin status. secondary parameters for oncological and erectile outcomes were assessed before and one year after surgery.

Eligibility criteria:
inclusion criteria: * preoperatively planed and intraoperatively performed nerve-sparing approach (at least unilateral) * suitable pelvic mri for the creation of a personalized 3d prostate model, * written patient consent exclusion criteria: * no nerve sparing performed

Keywords: prostatectomy nerve sparing 3d model urology frozen section
the impact of different carbohydrate restriction after a gastric bypass on the ketosis and ketoacidosis

Conditions: Obesity, Morbid; NASH; Ketosis; Keto Acidosis; Carbohydrate Metabolism Disorder

Summary: background: ketosis after bariatric surgery is a metabolic process that occurs when the body breaks down fat for energy because of not getting enough carbohydrates. insufficient production of ketone bodies reduces the rate of weight loss, and excessive amounts of ketones can lead to ketoacidosis or liver failure in patients with nonalcoholic steatohepatitis (nash). the investigators hypothesize that weight loss is directly related to calorie intake, and a significant reduction in carbohydrate content leads to increased ketosis and the risk of ketoacidosis. objectives: the study aimed to compare the incidence of ketoacidosis and liver failure in patients with nash with different intakes of carbohydrates in the early postoperative period after gastric bypass. in addition, the investigators want to find out how carbohydrate restriction will affect weight loss for up to 1 year.

methods: this study is a three-arm randomized controlled trial. all patients will undergo laparoscopic one anastomotic gastric bypass. in the postoperative period, all patients will receive normal daily amounts of protein and fat. depending on the amount of carbohydrates that will be received after surgery, patients will randomly (no mask) be divided into three groups: the first group: 51-75% deficit in carbohydrates second group: 26-50% deficit in carbohydrates the third group: has a 1-25% deficit in carbohydrates. primary outcome measurement compare the incidence of ketoacidosis and liver failure in three groups of patients with nash with different intakes of carbohydrates in the early postoperative period after gastric bypass. secondary outcome measurements change in body mass index (δ bmi). effect weight loss for up to 1 year.

Eligibility criteria:
inclusion criteria: * obesity patients bmi 30-50 kg/m2. * patients with nonalcoholic steatohepatitis (nash). exclusion criteria: * patients with active physical sports * diabetes * cirrhosis

Keywords: carbohydrate restriction ketosis after bariatric surgery
cardiovascular patients with no standard modifiable risk factors

Conditions: Cardiovascular Risk Factors

Summary: a growing number of patients develop atherosclerotic cardiovascular disease (ascvd) despite the absence of standard modifiable risk factors (smurf-less). there is scarcity of studies that address this issue in the middle eastern population.

atherosclerotic coronary artery disease (ascad) claims millions of lives annually on a global level and is the leading cause of death in the middle east. there are four standard modifiable cardiovascular risk factors (smurfs): hypertension, type 2 diabetes mellitus, dyslipidemia, and smoking. these are very common in the middle east and are crucial to be screened for and addressed in an affective manner. however, an increasing proportion of patients with ascvd have none of these individual factors (smurf-less). globally, this proportion comprises 11.6% of individuals with stable coronary disease and heart attack. no prior study has addressed the issue of the prevalence of smurf-less patients among the whole population of individuals with ascvd in the middle east.

Eligibility criteria:
inclusion criteria: * a diagnosis of atherosclerotic cardiovascular disease (ascvd). * ability to fill the clinical form that evaluates the presence or absence of cardiovascular risk factors including the 4 smurfs. exclusion criteria: * atherosclerotic cardiovascular disease diagnosed before the age of 18 years. * inability to give detailed history of prespecified risk factors.

Keywords: atherosclerotic cardiovascular disease standard modifiable risk factors (smurfs) middle eastern population
a 24-weeks, multi-center, randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of donepezil hydrochloride in chinese subjects with severe alzheimer's disease

Conditions: Alzheimer's Type Dementia

Summary: the objective is to demonstrate that donepezil hydrochloride 10 mg/day has superior efficacy compared with placebo in cognitive function in chinese subjects with severe alzheimer's disease.


Eligibility criteria:
inclusion criteria * written informed consent (ic) will be obtained from the subject (if possible) or from the subject's legal guardian or legal representative prior to beginning screening activities. * subject age range: male and female subjects 50 to 90 years of age, inclusive * diagnosis: diagnostic evidence of probable alzheimer's disease (ad) consistent with diagnostic and statistical manual of mental disorders, fourth edition, text revision (dsm-iv-tr) and national institute of neurological and communicative disorders and stroke-alzheimer's disease and related disorders association (nincds-adrda) criteria * mmse 1 to 12 inclusive, at both screening and baseline * sib less than or equal to 90 and greater than or equal to 10 at both screening and baseline * comorbid medical conditions must be clinically stable prior to baseline, unless otherwise specified. exclusion criteria * subjects with a known history of disorders that affect cognition or the ability to assess cognition, but are distinguishable from ad * evidence of focal disease to account for dementia on any cranial image mri or ct. * subjects with dementia complicated by other organic disease or ad with delirium according to dsm-iv criteria * subjects who cannot swallow or who have difficulty swallowing whole tablets, as tablets should not be broken or crushed * illiteracy prior to ad * subjects who are unwilling or unable to fulfill the requirements of the study * treatment with another cholinesterase inhibitor and/or memantine in the 3 months prior to screening * subjects with a poor response (tolerability) to prior exposure to donepezil

Keywords: alzheimer disease dementia delirium amnestic cognitive disorders donepezil brain diseases central nervous system diseases nervous system diseases tauopathies neurodegenerative diseases mental disorders cholinesterase inhibitors enzy